COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7226-7230

  Dornan, David ^a   Bheddah, Sheila ^a   Newton, Kim ^a   Inice, William ^a   Frantz, Gretchen D ^a   Dowd, Patrick ^b   Koeppen, Hartmut ^a   Dixit, Vishva M ^a   French, Dorothy M ^a,b  

^a Department of Molecular Oncology ^*  (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; PROTEASOME; PROTEIN P53;

ACCELERATION; ARTICLE; BIOTRANSFORMATION; BREAST ADENOCARCINOMA; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA MICROARRAY; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; STRESS; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; OVARIAN NEOPLASMS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 5644302246     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2601     Document Type: Article

References (20)

1. Hupp TR, Lane DP, Ball KL. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000;352:1-17.
2. Ho J, Benchimol S. Transcriptional repression mediated by the p53 tumour suppressor. Cell Death Differ 2003;10:404-8.
3. Beroud C, Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum Mutat 2003;21:176-81.
4. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
5. Leng RP, Lin Y, Ma W, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell 2003;112:779-91.
6. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;387:296-9.
7. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature (Lond) 1997;387:299-303.
8. Leach FS, Tokino T, Meltzer P, et al. p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993;53:2231-4.
9. McCann AH, Kirley A, Carney DN, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995;71:981-5.
10. Ho GH, Calvano JE, Bisogna M, et al. Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma. Breast Cancer Res. Treat 2001;65:225-32.
11. Fakharzadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
12. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
13. Hardtke CS, Gohda K, Osterlund MT, Oyama T, Okada K, Deng XW. HY5 stability and activity in arabidopsis is regulated by phosphorylation in its COP1 binding domain. EMBO J 2000;19:4997-5006.
14. Bianchi E, Denti S, Catena R, et al. Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity. J Biol Chem 2003;278:19682-90.
15. Wertz IE, O'Rourke KM, Zhang Z, et al. Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science (Wash DC) 2004;303:1371-4.
16. Cao Y, Gao Q, Wazer DE, Band V. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells. Cancer Res 1997;57:5584-9.
17. Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A, Hupp TR. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 1999;342:133-41.
18. Bueso-Ramos CE, Manshouri T, Haidar MA, et al. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res. Treat 1996;37:179-88.
19. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736-9.
20. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat 2003;21:285-91.